Van de Werf F - Search Results

1

Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.

Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F. Holvoet P, et al. Among authors: van de werf f. Arterioscler Thromb Vasc Biol. 2001 May;21(5):844-8. doi: 10.1161/01.atv.21.5.844. Arterioscler Thromb Vasc Biol. 2001. PMID: 11348884 Free article.

2

Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.

Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Holvoet P, et al. Among authors: van de werf f. Circulation. 1998 Oct 13;98(15):1487-94. doi: 10.1161/01.cir.98.15.1487. Circulation. 1998. PMID: 9769301 Free article.

3

Malondialdehyde-modified LDL as a marker of acute coronary syndromes.

Holvoet P, Collen D, Van de Werf F. Holvoet P, et al. Among authors: van de werf f. JAMA. 1999 May 12;281(18):1718-21. doi: 10.1001/jama.281.18.1718. JAMA. 1999. PMID: 10328072

4

Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction.

Collen D, Van de Werf F. Collen D, et al. Among authors: van de werf f. Circulation. 1993 Jun;87(6):1850-3. doi: 10.1161/01.cir.87.6.1850. Circulation. 1993. PMID: 8504497

5

A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.

Vanderschueren S, Collen D, van de Werf F. Vanderschueren S, et al. Among authors: van de werf f. Thromb Haemost. 1996 Oct;76(4):541-4. Thromb Haemost. 1996. PMID: 8902993 Clinical Trial.

6

Comparative copper coil-induced thrombogenicity of the internal mammary, left anterior descending coronary, and popliteal arteries in dogs.

Rapold HJ, Stassen T, Van de Werf F, Collen D. Rapold HJ, et al. Among authors: van de werf f. Arterioscler Thromb. 1992 May;12(5):639-44. doi: 10.1161/01.atv.12.5.639. Arterioscler Thromb. 1992. PMID: 1576125

7

Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction.

Van de Werf F, Lijnen HR, Collen D. Van de Werf F, et al. Coron Artery Dis. 1993 Oct;4(10):929-33. doi: 10.1097/00019501-199310000-00013. Coron Artery Dis. 1993. PMID: 8269200

8

Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.

Cambier P, van de Werf F, Larsen GR, Collen D. Cambier P, et al. Among authors: van de werf f. J Cardiovasc Pharmacol. 1988 Apr;11(4):468-72. doi: 10.1097/00005344-198804000-00013. J Cardiovasc Pharmacol. 1988. PMID: 2453751

9

A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters.

Jacobs H, Van de Werf F, Lesaffre E, De Geest H, Collen D. Jacobs H, et al. Among authors: de geest h, van de werf f. Acta Clin Belg. 1992;47(2):82-9. doi: 10.1080/17843286.1992.11718214. Acta Clin Belg. 1992. PMID: 1352930 Clinical Trial.

10

Fibrin-selective thrombolytic therapy with recombinant staphylokinase.

Collen D, Vanderschueren S, Van de Werf F. Collen D, et al. Among authors: van de werf f. Haemostasis. 1996 Oct;26 Suppl 4:294-300. doi: 10.1159/000217310. Haemostasis. 1996. PMID: 8979135 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

759 results

Search Page

Filters